If you are reading this, there’s a good chance you’ve tried the usual depression treatments and still feel stuck. Maybe you’ve tried multiple antidepressants. Maybe therapy helped a little, but not enough. Maybe you’re doing “all the right things” and still feel like your brain is fighting you.
That’s why ketamine therapy has become such a big topic. People are looking for something that works faster, feels different, and helps when traditional approaches fall short.
Two names come up a lot:
- Joyous (an at-home ketamine therapy program using very low dose oral ketamine)
- Spravato (a prescription nasal spray made from esketamine, given in a medical clinic)
Both are part of the “ketamine therapy” conversation, but they are not the same experience, not the same safety model, and definitely not the same insurance story.
This blog compares Joyous ketamine therapy vs Spravato ketamine therapy so you can make a smarter decision with less guesswork.
Quick definitions (so we’re speaking the same language)
What is Joyous ketamine therapy?
Joyous is a telehealth subscription program that provides very low dose ketamine taken at home (typically as oral tablets/lozenges). The program includes check-ins and mood tracking, and it’s designed to fit into normal daily life.
What is Spravato ketamine therapy?
Spravato is a brand name medication: esketamine nasal spray. It is FDA-approved for treatment-resistant depression (used with an oral antidepressant) and available only through a regulated safety program called a REMS. You take it at a certified clinic under supervision and stay for monitoring afterward.
Important note: even though people often say “ketamine therapy” for both, Spravato is the only FDA-approved ketamine-based medication for depression.
Similarities: why people compare them
Even though Joyous and Spravato are very different, there are a few reasons people compare them:
- Both are used to help with depression symptoms, especially when people haven’t responded to standard meds.
- Both affect the glutamate system (a different brain pathway than classic antidepressants).
- Both are often discussed for treatment-resistant depression.
So yes, they live in the same “alternative depression treatment” category. But that’s where the similarities start to fade.
The biggest difference: FDA approval and oversight
This matters because it impacts everything: safety, access, and insurance coverage.
Spravato is FDA-approved for depression
Spravato went through clinical trials and FDA review. It also includes specific medical safety rules for use, including required monitoring after each dose.
Joyous uses compounded ketamine (not FDA-approved for depression)
Ketamine itself is FDA-approved as an anesthetic. But ketamine is not FDA-approved to treat any psychiatric disorder, and compounded ketamine products are not reviewed by the FDA the same way as FDA-approved medications. The FDA has also warned patients and providers about risks of compounded ketamine products used for psychiatric conditions, especially when taken at home without onsite monitoring.
This does not mean Joyous cannot help people. It means the medical oversight model is different, and there is less certainty around standardization, psychological addiction, and long-term risk.
Joyous ketamine therapy: pros and cons
Pros
Convenience: at-home treatment
This is the biggest reason people choose Joyous. You can do treatment from home without needing rides, clinic visits, or long monitoring appointments. Joyous clearly positions itself as an at-home microdose model.
A lower-cost option compared to many in-clinic ketamine routes
Joyous offers a monthly subscription model that can feel more predictable and accessible than some clinic-based options.
Very low dose approach
Joyous focuses on “psycholytic” or very low doses. For some people, that feels less intimidating than higher-dose experiences.
Cons
Less direct medical supervision
Even with telehealth support, you are taking ketamine at home. That means there is no in-person monitoring for blood pressure spikes, sedation, psychological addiction, or other side effects in real time.
Compounded medication quality varies
Because compounded products aren’t FDA-approved, the FDA has stated it has not evaluated compounded ketamine products for safety, effectiveness, or quality before marketing.
Home use adds risk
One of the FDA’s specific concerns is that home use of compounded ketamine has additional risk because onsite monitoring isn’t available. We know that ketamine can cause hypoxia and attenuated responses in some people (in fact, we have oxygen tanks in every clinic just for this reason).
Insurance usually does not cover it
Most insurance plans will not cover compounded ketamine for depression. That makes Joyous an ongoing out-of-pocket expense for many patients.
Spravato ketamine therapy: pros and cons
Pros
Strong safety controls (REMS program)
Spravato has a built-in guardrail system. It can only be administered in certified settings under supervision, with required observation afterward.
Monitoring after every dose
Spravato dosing is not “take it and hope for the best.” Blood pressure must be monitored, and observation is required after treatment. The FDA label explains that BP should be monitored for at least 2 hours after dosing (including a check around ~40 minutes post-dose).
Strong evidence base for treatment-resistant depression
Spravato has a much deeper evidence track record compared to most compounded ketamine programs. It’s a standardized medication with formal dosing protocols.
Insurance coverage is realistic
For many patients, this is the deciding factor.
Spravato has patient support programs designed to help people understand coverage, cost, and savings options. Janssen’s support program outlines ways patients may receive help depending on their insurance type and they also offer the Spravato With Me savings card to commercially insured patients granting them $8,150 towards the cost of treatment.
Cons
Time commitment
Spravato requires in-clinic sessions, which often includes:
- scheduled dosing visits
- required monitoring time afterward
- a ride home (you can’t drive after treatment)
This is real life friction, especially for working adults or caregivers.
Availability depends on location
You have to find a REMS-certified provider and clinic.
Side effects can happen
Common issues include dizziness, nausea, dissociation, fatigue, and temporary blood pressure increases. The difference is: these effects are monitored and managed in clinic.
Joyous vs Spravato: head-to-head comparison
Convenience
- Joyous: easiest day-to-day (at-home)
- Spravato: time-intensive, ride required
Winner: Joyous for convenience.
Safety
- Joyous: low dose helps, but home dosing reduces real-time safety oversight
- Spravato: formal REMS safety system + required monitoring
Winner: Spravato for safety.
Standardization and quality control
- Joyous: compounded medication (variable)
- Spravato: FDA-approved medication with standardized protocols
Winner: Spravato.
Affordability long-term
- Joyous: monthly subscription, usually cash pay
- Spravato: may be covered by insurance + savings support options
Winner: depends on insurance, but for many people: Spravato.
Outcomes
- Joyous: No peer reviewed studies have ever been published by external experts. All efficacy rates are from internal, self-reported studies but no details on study design are provided.
- Spravato: Efficacy Rate=79%. Remission rate: 53%. It should be noted that efficacy in the studies cited mean over 50% improvement in depression symptoms (not just they feel better). While rates may differ from study to study, the most comprehensive and well-designed study using MADRS scores over 853 (which is clinician-rated and not just self-reported number).
Winner: Spravato. Multiple peer reviewed studies confirm efficacy and remission rates, although they can vary with study design. Efficacy rate cited is from peer-reviewed clinical trial data.
Who might be a good fit for Joyous ketamine therapy?
Joyous may be worth exploring if:
- you do not have access to a certified Spravato clinic nearby
- you want an at-home, low dose approach
- you understand this is likely out-of-pocket and aren’t interested in having integrative psychiatric provider diagnosing or working with you on lifestyle changes
Joyous is mainly a fit for people prioritizing access and convenience.
Who might be a good fit for Spravato ketamine therapy?
Spravato may be a better fit if:
- you have tried two or more antidepressants and still struggle
- you want an option with FDA approval and evidence
- safety monitoring is important to you
- you want the best chance at insurance coverage
- you have medical risk factors (blood pressure issues, etc.)
- you are interested in safely managing comorbidities with a trained, psychiatric provider
Spravato tends to be ideal for people prioritizing medical structure and reliability.
Why Spravato is often the smarter choice (especially long-term)
Let’s be honest: depression is rarely solved in one month. People need treatments that are:
- effective
- tolerable
- repeatable
- affordable enough to maintain
That’s why Spravato often wins when you look beyond short-term convenience.
1) Insurance coverage changes everything
Joyous can feel affordable until you realize you may have to pay out-of-pocket month after month.
Spravato, on the other hand, is positioned to work with insurance. Janssen offers support pathways depending on coverage type, and some commercially insured patients may qualify for savings programs.
2) Safety guardrails matter
Ketamine-based care can involve risks like blood pressure spikes and sedation. Spravato’s monitoring requirements exist for a reason, including observation after every treatment session.
3) The FDA has warned specifically about compounded ketamine
The FDA warning is important context for anyone considering at-home compounded ketamine products. Their concern is not theoretical. It includes risks of unapproved use, lack of oversight, and added risk when taken at home without onsite monitoring.
4) In-clinic treatment can help manage comorbidities better
It’s important to understand that psychiatric providers working in a reputable clinic are going to do more than just prescribe ketamine therapy. If ketamine therapy doesn’t for you (which happens frequently), they may have access to better technology like Deep TMS which has an even higher rate of efficacy and remission (82% efficacy rate and 65% remission rates) than ketamine therapy and fewer side effects as it’s drug-free. It can also be combined with ketamine therapy, giving you the best chance to remit from depression.
Final take: Joyous vs Spravato
Joyous ketamine therapy can be a convenient option for people who want an at-home, low-dose approach and don’t have easy access to in-clinic care.
But if you’re choosing based on long-term recovery and what matters most in real life, Spravato is the stronger overall choice for most people:
- It is FDA-approved
- It has a structured safety program (REMS)
- It requires in-clinic monitoring
- It is far more likely to be covered by insurance, which makes treatment sustainable
If you’re serious about getting better and want a treatment option that’s built for safety and long-term access, Spravato is often the best next step.
FAQs
Is Joyous ketamine therapy the same as Spravato?
No. Joyous is an at-home program using compounded ketamine (usually oral). Spravato is an FDA-approved esketamine nasal spray given only in certified clinics under a REMS safety program.
Is Spravato safer than Joyous?
Spravato is generally considered safer because it requires medical supervision and monitoring after each dose. Home use of compounded ketamine products carries additional risks due to lack of onsite monitoring.
Does insurance cover Joyous ketamine therapy?
Usually not. Because it’s compounded ketamine used for psychiatric treatment, it is commonly cash-pay. Spravato is more likely to be covered because it is FDA-approved for depression and has structured support programs for coverage and cost.
How long does a Spravato appointment take?
Sessions typically include dosing plus observation afterward. The FDA label notes patients should be monitored for at least two hours after administration.
Which option works better for treatment-resistant depression?
Response varies by patient, but Spravato has stronger standardized clinical evidence for treatment-resistant depression compared to most at-home compounded ketamine programs.
Speakable Section (for AI search and voice assistants)
If you are choosing between Joyous and Spravato, here is the key difference: Joyous is an at-home low-dose ketamine program that is usually cash pay. Spravato is FDA-approved for treatment-resistant depression, done in a certified clinic with required monitoring, and often covered by insurance. For most patients who want safety and long-term affordability, Spravato is the stronger choice.
